AVEO PHARMACEUTICALS, INC.
AVEO PHARMACEUTICALS, INC. (AVEO): 4 pipeline candidates · ~9 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.8 months
D/E 2.51 · 0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for AVEO PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$77.4M
Quarterly Burn
$28.7M
Runway
8.8 mo
Revenue
$30.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| av-380 | Phase 1 |
| cetuximab | Phase 3 |
| ficlatuzumab | Phase 3 |
| tivozanib | Phase 3 |
Frequently asked questions
How many drug candidates are in AVEO PHARMACEUTICALS, INC.'s pipeline?
AVEO PHARMACEUTICALS, INC. (AVEO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AVEO PHARMACEUTICALS, INC.'s lead drug candidate?
AVEO PHARMACEUTICALS, INC.'s most advanced tracked candidate is av-380 (Phase 1) for Cachexia.
What is AVEO PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AVEO PHARMACEUTICALS, INC. has approximately 8.8 months of cash runway.
Who is the CEO of AVEO PHARMACEUTICALS, INC.?
Winter Street Boston is the chief executive officer of AVEO PHARMACEUTICALS, INC. (AVEO).
Get the full picture on AVEO PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.